About Us

Glen Research develops, manufactures and markets reagents for oligonucleotide synthesis, modification, labeling and purification. The company serves customers worldwide involved in basic research, diagnostics and therapeutics. Although Glen Research’s mission was to provide state-of-the-art reagents to researchers, the company also began offering standard reagents for oligonucleotide synthesis but with the innovation that every batch was accompanied by a Certificate of Analysis. The analytical techniques and quality criteria used for the evaluation and acceptance of these reagents was to become an industry standard years later. The company is headquartered in Sterling, Virginia. A privately held company, Glen Research was acquired by Maravai LifeSciences in December 2017.

Glen Research Facility

30 Years of Assured Quality for Oligo Synthesis

1987

Glen Research was incorporated in the Commonwealth of Virginia

1991

Company awarded SBIR grant for the investigation of large scale oligonucleotide synthesis using H-phosphonate chemistry

1993

Glen Research introduced the Sterling line of products, a new standard of accomplishment for oligonucleotide synthesis

1995

Glen Research negotiated an exclusive agreement to supply 5’-biotin phosphoramidite worldwide

1996

Company negotiated an exclusive license with Gilead Sciences to supply C5-propynyl pyrimidine nucleosides and G-Clamp phosphoramidites

1997

Glen Research moves into a custom built building in Sterling, Virginia

1999

Company awarded patents for a chemical phosphorylation reagent compatible with DMT-ON purification

2002

Company made an agreement with Epoch Biosciences, Inc. to supply their proprietary dyes and nucleosides to the research market

2003

Glen Research negotiated an agreement with GE Healthcare Biosciences Corp. to supply Cyanine Dyes to the research market

2004

Company awarded patents for a truly universal support for oligonucleotide synthesis - US III.

2006

In collaboration with Berry & Associates, Glen Research awarded patents for pyrrolo-C analogues, fluorescent C analogues

2008

Glen Research obtained a license for the sale of Glen UnySupport from Ionis Pharmaceuticals

2013

In collaboration with Nelson Biotechnologies, Inc., company awarded patent for serinol phosphoramidites and supports

2017

Glen Research is acquired by Maravai LifeSciences

Company Information

Year Founded:
1987
Number of Employees:
20+
Facilities:
Headquarters, Sterling, VA USA
Key Personnel:
Christine Dolan, Chief Operating Officer
Christine was appointed COO for Glen Research in October 2018. She is accountable for all operations including designing/implementing business processes and organizational structures/strategies to ensure continued longevity and growth. She also leads the Operations for Cygnus Technologies LLC, under the Maravai portfolio. Prior to joining Maravai, she was the SVP of Product Development at Catalent Pharma Solutions and served in several senior global Quality, Operations and Business Unit leadership roles during her 8 year tenure. In addition, she has held progressive operational management roles at GE Healthcare and Amersham Health. Christine started her career as a microbiologist, and holds a B.S. in Biology from Lenoir Rhyne College.

David Weber, VP and Chief Commercial Officer
David comes to Maravai LifeSciences with over 35 years of experience in life sciences industry commercial leadership and general management. David is responsible for all marketing, sales, product development, commercial strategy, service and support for all Maravai LifeSciences portfolio companies. Prior to joining Maravai LifeSciences, David served as Executive Vice President and Chief Commercial Officer for Affymetrix leading up to its acquisition by Thermo Fisher Scientific. Earlier in his career, David held a variety of commercial leadership roles in life science companies including Amersham Biosciences (GE Healthcare), Eksigent Technologies, Cyntellect, Stratagene and The Linus Group.

Harjit Kullar, VP, Marketing
Harjit comes to Maravai LifeSciences with over 15 years of experience in sales and marketing in the life sciences and diagnostics industries, most recently holding the position of Vice President of Marketing at Transgenomic. Earlier in his career, Harjit held a variety of commercial leadership roles in life science companies including Bio-Rad Laboratories, Thermo Fisher Scientific, Life Technologies, LifeSpan BioSciences and Abcam. Harjit received a BSc in Biochemistry & Pharmacology from University of Southampton, a Ph.D. in Cancer Biology from University of Birmingham and an MBA from University of Cambridge.
Contacts for the Media:
Jennifer Dahlgren
Dahlgren Communications
(530) 263-6817
[email protected]